341 related articles for article (PubMed ID: 29981298)
1. Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis.
Telesco SE; Brodmerkel C; Zhang H; Kim LL; Johanns J; Mazumder A; Li K; Baribaud F; Curran M; Strauss R; Paxson B; Plevy S; Davison T; Knight L; Dibben S; Schreiber S; Sandborn W; Rutgeerts P; Siegel CA; Reinisch W; Greenbaum LE
Gastroenterology; 2018 Oct; 155(4):1008-1011.e8. PubMed ID: 29981298
[TBL] [Abstract][Full Text] [Related]
2. Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis.
Tew GW; Hackney JA; Gibbons D; Lamb CA; Luca D; Egen JG; Diehl L; Eastham Anderson J; Vermeire S; Mansfield JC; Feagan BG; Panes J; Baumgart DC; Schreiber S; Dotan I; Sandborn WJ; Kirby JA; Irving PM; De Hertogh G; Van Assche GA; Rutgeerts P; O'Byrne S; Hayday A; Keir ME
Gastroenterology; 2016 Feb; 150(2):477-87.e9. PubMed ID: 26522261
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and Safety of Golimumab in Treating Outpatient Ulcerative Colitis: A Real-Life Prospective, Multicentre, Observational Study in Primary Inflammatory Bowel Diseases Centers.
Tursi A; Allegretta L; Buccianti N; Della Valle N; Elisei W; Forti G; Faggiani R; Gallina S; Hadad Y; Larussa T; Lauria A; Luzza F; Lorenzetti R; Mocci G; Penna A; Polimeni N; Pranzo G; Ricciardelli C; Zampaletta C; Picchio M
J Gastrointestin Liver Dis; 2017 Sep; 26(3):239-244. PubMed ID: 28922435
[TBL] [Abstract][Full Text] [Related]
4. Golimumab for moderate to severe ulcerative colitis.
Strik AS; Berends SE; Mathôt RA; D'Haens GR; Löwenberg M
Expert Rev Gastroenterol Hepatol; 2017 May; 11(5):401-406. PubMed ID: 28276288
[TBL] [Abstract][Full Text] [Related]
5. Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study.
Bosca-Watts MM; Cortes X; Iborra M; Huguet JM; Sempere L; Garcia G; Gil R; Garcia M; Muñoz M; Almela P; Maroto N; Paredes JM
World J Gastroenterol; 2016 Dec; 22(47):10432-10439. PubMed ID: 28058024
[TBL] [Abstract][Full Text] [Related]
6. Variability in Golimumab Exposure: A 'Real-Life' Observational Study in Active Ulcerative Colitis.
Detrez I; Dreesen E; Van Stappen T; de Vries A; Brouwers E; Van Assche G; Vermeire S; Ferrante M; Gils A
J Crohns Colitis; 2016 May; 10(5):575-81. PubMed ID: 26738756
[TBL] [Abstract][Full Text] [Related]
7. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.
Colombel JF; Rutgeerts P; Reinisch W; Esser D; Wang Y; Lang Y; Marano CW; Strauss R; Oddens BJ; Feagan BG; Hanauer SB; Lichtenstein GR; Present D; Sands BE; Sandborn WJ
Gastroenterology; 2011 Oct; 141(4):1194-201. PubMed ID: 21723220
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Rutgeerts P;
Gastroenterology; 2014 Jan; 146(1):96-109.e1. PubMed ID: 23770005
[TBL] [Abstract][Full Text] [Related]
9. Golimumab for moderately to severely active ulcerative colitis.
Kedia S; Ahuja V; Makharia GK
Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1273-82. PubMed ID: 27498886
[TBL] [Abstract][Full Text] [Related]
10. Endoscopic and clinical variables that predict sustained remission in children with ulcerative colitis treated with infliximab.
Turner D; Griffiths AM; Veerman G; Johanns J; Damaraju L; Blank M; Hyams J
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1460-5. PubMed ID: 23672831
[TBL] [Abstract][Full Text] [Related]
11. Ultrastructural evidence of mucosal healing after infliximab in patients with ulcerative colitis.
Fratila OC; Craciun C
J Gastrointestin Liver Dis; 2010 Jun; 19(2):147-53. PubMed ID: 20593047
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Hibi T; Rutgeerts P;
Gastroenterology; 2014 Jan; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
[TBL] [Abstract][Full Text] [Related]
13. Repeated intensified infliximab induction - results from an 11-year prospective study of ulcerative colitis using a novel treatment algorithm.
Johnsen KM; Goll R; Hansen V; Olsen T; Rismo R; Heitmann R; Gundersen MD; Kvamme JM; Paulssen EJ; Kileng H; Johnsen K; Florholmen J
Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):98-104. PubMed ID: 27749779
[TBL] [Abstract][Full Text] [Related]
14. Ulcerative colitis patients in clinical remission demonstrate correlations between fecal immunochemical test results, mucosal healing, and risk of relapse.
Nakarai A; Kato J; Hiraoka S; Takashima S; Takei D; Inokuchi T; Sugihara Y; Takahara M; Harada K; Okada H
World J Gastroenterol; 2016 Jun; 22(21):5079-87. PubMed ID: 27275100
[TBL] [Abstract][Full Text] [Related]
15. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis.
Arijs I; Li K; Toedter G; Quintens R; Van Lommel L; Van Steen K; Leemans P; De Hertogh G; Lemaire K; Ferrante M; Schnitzler F; Thorrez L; Ma K; Song XY; Marano C; Van Assche G; Vermeire S; Geboes K; Schuit F; Baribaud F; Rutgeerts P
Gut; 2009 Dec; 58(12):1612-9. PubMed ID: 19700435
[TBL] [Abstract][Full Text] [Related]
16. Baseline risk assessment of patients with ulcerative colitis: does initial treatment selection influence outcomes?
Mosli M; Alfaer S; Almalaki T; Albeshry A; Aljehani S; Alshmrani B; Habib Z; Jawa H; Qari Y
Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):80-85. PubMed ID: 30199472
[TBL] [Abstract][Full Text] [Related]
17. Golimumab effectiveness and safety in clinical practice for moderately active ulcerative colitis.
O'Connell J; Rowan C; Stack R; Harkin G; Parihar V; Chan G; Breslin N; Cullen G; Dunne C; Egan L; Harewood G; Leyden J; MacCarthy F; MacMathuna P; Mahmud N; McKiernan S; McNamara D; Mulcahy H; Murray F; O'Connor A; O'Toole A; Patchett S; Ryan B; Sheridan J; Slattery E; Doherty G; Kevans D
Eur J Gastroenterol Hepatol; 2018 Sep; 30(9):1019-1026. PubMed ID: 29878945
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis.
Sandborn WJ; Cyrille M; Hansen MB; Feagan BG; Loftus EV; Rogler G; Vermeire S; Cruz ML; Yang J; Boedigheimer MJ; Abuqayyas L; Evangelista CM; Sullivan BA; Reinisch W
Gastroenterology; 2019 Mar; 156(4):946-957.e18. PubMed ID: 30472236
[TBL] [Abstract][Full Text] [Related]
19. Fecal Calprotectin Predicts Mucosal Healing in Patients With Ulcerative Colitis Treated With Biological Therapies: A Prospective Study.
Bertani L; Blandizzi C; Mumolo MG; Ceccarelli L; Albano E; Tapete G; Baiano Svizzero G; Zanzi F; Coppini F; de Bortoli N; Bellini M; Morganti R; Marchi S; Costa F
Clin Transl Gastroenterol; 2020 May; 11(5):e00174. PubMed ID: 32677804
[TBL] [Abstract][Full Text] [Related]
20. Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis - results from multicenter observational cohort.
Bálint A; Rutka M; Kolar M; Bortlik M; Duricova D; Hruba V; Lukas M; Mitrova K; Malickova K; Lukas M; Szepes Z; Nagy F; Palatka K; Lovas S; Végh Z; Kürti Z; Csontos Á; Miheller P; Nyári T; Bor R; Milassin Á; Fábián A; Szántó K; Lakatos PL; Molnár T; Farkas K
Expert Opin Biol Ther; 2018 Nov; 18(11):1181-1187. PubMed ID: 30277084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]